ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

Á¥ÊôµÚÁùÒ½ÔºÑо¿Ð§¹ûÖúÁ¦Ö±³¦°©NCCNÖ¸ÄÏË¢ÐÂ

¸å¼þȪԴ£º£º£ºÁ¥ÊôµÚÁùÒ½Ôº ±à¼­£º£º£ºÖ£Áú·É¡¢Íõ¶¬Ã· ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±¼òÎÄÑî¡¢´÷Ï£°²£©ÃÀ¹ú¹ú¼Ò×ۺϰ©Ö¢ÍøÂ磨NCCN£©ÊÇÓɶà¼Ò¶¥¼¶°©Ö¢ÖÐÐÄ×é³ÉµÄѧÊõ×éÖ¯¡£¡£¡£NCCNƾ֤×îеÄѭ֤ҽѧ֤¾Ý£¬£¬ £¬Ã¿ÄêÐû²¼ÖÖÖÖ¶ñÐÔÖ×Áö×îеÄNCCNÖ¸ÄÏ£¬£¬ £¬³ÉΪȫÇòÖ×ÁöÁÙ´²Êµ¼ùÓ¦ÓÃ×îΪÆÕ±éµÄÁÙ´²Ö¸ÄÏ£¬£¬ £¬»ñµÃÁËÈ«ÇòÁÙ´²Ò½Ê¦µÄÈϿɺÍ×ñÕÕ¡£¡£¡£

¿ËÈÕ£¬£¬ £¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½ÔºÑо¿ÍŶӷ¢Ã÷£¬£¬ £¬ÏÖÔÚµÄÖ±³¦°©ÖÎÁƺó¼à²â·½°¸ÔÚ»ùÏßCEAÕý³£»£»¼ÕßÖб£´æÈ±·¦¡£¡£¡£Ñо¿Ð§¹û¡°Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA¡±ÔÚNCCN¹Ù·½ÆÚ¿¯JNCCNÔÚÏß½ÒÏþ£¬£¬ £¬ÎªNCCNÖ¸ÄÏÖÐÖ±³¦°©Ëæ·Ã¼ì²â·½°¸µÄ¸üУ¬£¬ £¬ÌṩÁ˸߼ÛÖµµÄѭ֤ҽѧ֤¾Ý¡£¡£¡£¸ÃԺ賦²¡Ñ§Ñо¿ËùÓí»ã´¨ÎªÂÛÎĵÄͨѶ×÷Õߣ¬£¬ £¬²©Ê¿Ñо¿ÉúÉ궦³ÉΪÂÛÎĵĵÚÒ»×÷Õß¡£¡£¡£

°©Åß¿¹Ô­£¨CEA£©ÊÇÓÉGoldºÍFreedmanÔÚ1965ÄêÊ×Ïȴӽ᳦°©ºÍÅßÌ¥×éÖ¯ÖÐÌáÈ¡µÄÒ»ÖÖÖ×ÁöÏà¹Ø¿¹Ô­¡£¡£¡£CEAÔÚÈËÌåÆ÷¹Ù¡¢×éÖ¯¼°ÖÖÖÖÌåÒºÖоùÈÝÒ×¼ì³öÇÒ¼ì²â¾ßÓÐÎÞ´´ÐÔ¡¢±ê×¼»¯ÒÔ¼°±¾Ç®µÍµÈÓŵã¡£¡£¡£¾­´ó×ÚÁÙ´²Êµ¼ù֤ʵ£¬£¬ £¬CEA×÷ΪһÖÖ¹ãÆ×Ö×Áö±ê¼ÇÎ£¬ £¬ÔÚÏû»¯µÀÖ×Áö¡¢ÃÚÄòϵÖ×Áö¡¢·Î°©¡¢Âѳ²°©¼°ÈéÏÙ°©µÈ¶àÖÖÖ×ÁöµÄÁÆÐ§ÆÀ¼Û¡¢²¡Çé¼à²âµÈ·½Ãæ¾ßÓÐÖ÷ÒªµÄÁÙ´²¼ÛÖµ¡£¡£¡£ÑªÇåCEAÕý³£²Î¿¼Õý³£ÖµÊÇ:0-5ug/L¡£¡£¡£

ƾ֤°üÀ¨NCCNÖ¸ÄÏÔÚÄڵĺ£ÄÚÍâȨÍþ½áÖ±³¦°©ÁÙ´²Ö¸ÄÏÍÆ¼ö£¬£¬ £¬¼ì²âCEA±»ÊÓΪ¼à²â½áÖ±³¦°©»¼ÕßÊõºóÊÇ·ñ¸´·¢×îÖ÷ÒªµÄ³õʼÊÖ¶ÎÖ®Ò»£¬£¬ £¬Ëæ·ÃÀú³ÌÖз¢Ã÷CEAÉý¸ßÍùÍùÄÜÔçÆÚÔ¤¾¯ÊõºóÖ×Áö¸´·¢£¬£¬ £¬²¢½øÒ»²½×ö³¦¾µ»òÓ°ÏñѧµÈ¼ì²é¾ÙÐÐÈ·Õͼ1£©¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ1 NCCNÖ¸ÄÏÖ±³¦°©ÖÎÁƺó¼à²â·½°¸£¨NCCN 2022 V1, REC-11£©

È»¶ø£¬£¬ £¬ÔÚÁÙ´²Êµ¼ùÀú³ÌÖУ¬£¬ £¬¸ÃÍŶӳÉÔ±·¢Ã÷£¬£¬ £¬¹ØÓÚÊõǰCEAÕý³£µÄÖ±³¦°©»¼Õߣ¬£¬ £¬Í¨¹ýÊõºóCEAÉý¸ßÀ´ÆðÔ´ÅжÏÖ×Áö¸´·¢×ªÒƵÄЧ¹ûÍùÍù²»²ÇÏë¡£¡£¡£Òò´Ë£¬£¬ £¬Ñо¿ÍŶÓÕë¶ÔÕâÒ»ÎÊÌ⣬£¬ £¬¿ªÕ¹ÁËÒ»Ïî×ÝÏòÐÐÁÐÑо¿£¨Í¼2£©¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ2 Á¥ÊôµÚÁùÒ½ÔºÍŶӿªÕ¹µÄ×ÝÏòÐÐÁÐÑо¿(Shen et al. JNCCN 2022)

Ñо¿Ð§¹ûÏÔʾ£¬£¬ £¬¹ØÓÚ»ùÏßCEAÕý³£µÄÖ±³¦°©»¼Õߣ¬£¬ £¬CEA¼à²âÖ×Áö¸´·¢µÄÃô¸Ð¶ÈÏÔÖøµÍÓÚ»ùÏßCEAÉý¸ßµÄ»¼Õß¡£¡£¡£Í¬Ê±£¬£¬ £¬CEAÁªºÏÌÇÀ࿹ԭCA19-9½Ïµ¥¶ÀCEAÏà±ÈÄÜÏÔÖøÌá¸ßÆäÔÚ»ùÏßCEAÕý³£×黼Õ߸´·¢¼à²âÖеÄÃô¸Ð¶È¡£¡£¡£Òò´Ë£¬£¬ £¬ÏÖÔÚÒÔCEAΪ»ù´¡µÄÊõºóËæ·Ã·½°¸ÔÚ»ùÏßCEAÕý³£µÄÖ±³¦°©»¼ÕßÖб£´æÈ±·¦¡£¡£¡£Ñо¿ÍŶӶÔNCCNÖ¸ÄÏÖÐÖ±³¦°©µÄÊõºóËæ·Ã·½°¸¾ÙÐÐÁ˸ÄÁ¼£¬£¬ £¬Ìá³öÁË¡°CEA·Ö²ã¼à²â·½°¸¡±£¬£¬ £¬Õë¶Ô²î±ðCEA»ùÏßÖµµÄ»¼ÕßÍÆ¼öÓëÖ®¶ÔÓ¦µÄËæ·Ã¼à²â·½°¸£¨Í¼3£©¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ3 Á¥ÊôµÚÁùÒ½ÔºÍŶÓÌá³öµÄÖ±³¦°©ÖÎÁƺóCEA·Ö²ã¼à²â·½°¸(Shen et al. JNCCN 2022)

±ðµÄ£¬£¬ £¬Ñо¿ÍŶӻ¹·¢Ã÷²¢½ç˵ÁËÒ»ÖÖCEAת»¯Ö×Áö£¨CEA-turn tumor£©£¬£¬ £¬Ô¼ÄªËÄ·ÖÖ®Ò»µÄ¸´·¢ÐÔÖ±³¦°©»¼ÕßΪCEAת»¯Ö×Áö£¬£¬ £¬ÆäÖ÷ÒªÌØÕ÷°üÀ¨ÖÎÁÆÇ°»ùÏßCEAÒõÐÔºÍÖÎÁƺ󸴷¢Ê±CEAÑôÐÔ¡£¡£¡£·ºÆðCEAת»¯µÄ¸´·¢ÐÔÖ±³¦°©»¼ÕßÌåÏÖ³öÔ½·¢¶ñÐÔµÄÖ×ÁöÉúÎïÑ§ÌØÕ÷£¬£¬ £¬¾ßÓиü²îµÄÔ¶ÆÚÉúÑÄϳ¡£¨Í¼4£©¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ4 CEAת»¯Ö×Áö»¼Õß¾ßÓиü²îµÄÔ¶ÆÚÉúÑÄϳ¡(Shen et al. JNCCN 2022)

ngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½ÔºÓµÓÐÌìÏÂ×î´óµÄ賦µÀÖ×ÁöÕïÁÆÖÐÐÄÖ®Ò»£¬£¬ £¬Ç£Í·Öƶ©ÁË¡¶Öйú½áÖ±³¦°©ÕïÁƹ淶¡·¡¢¡¶Öйú½áÖ±³¦°©É¸²éÓëÔçÕïÔçÖÎÖ¸ÄÏ¡·µÈ¶à²¿¹ú¼ÒÖ¸ÄÏ£¬£¬ £¬ÁìÏÎÁ˶àÏî¹ú¼ÒÖØµãÑз¢ÍýÏëÏîÄ¿£¬£¬ £¬ÓµÓжàÏîת»¯Â䵨µÄ¿Æ¼¼Á¢ÒìЧ¹û£¬£¬ £¬ÏÖÔÚ賦µÀÖ×ÁöÊý¾Ý¿âËæ·Ã¸ß´ï11ÍòÓàÈ˴Σ¬£¬ £¬½áÖ±³¦°©ÄêÊÖÊõÁ¿½ü4500Àý£¬£¬ £¬Ã¿ÄêÊÕÖεĽáÖ±³¦°©»¼Õß½ü3ÍòÈ˴Σ¨º¬·Å»¯ÁÆ£©£¬£¬ £¬ÎåÄê×ÜÉúÑÄÂʸߴï78%£¬£¬ £¬ÕïÁÆË®Æ½¾ÓÌìÏÂÒ»Á÷£¬£¬ £¬Îª¸ÃÑо¿µÄ˳Ë쿪չÌṩÁËÒªº¦µÄÖ§³Ö¡£¡£¡£ÕâЩÑо¿Ð§¹û¿ÉÄÜΪÒÔºóº£ÄÚÍâȨÍþ½áÖ±³¦°©Ö¸ÄÏÖÐÖ±³¦°©Ëæ·Ã·½°¸µÄ¸üÐÂÌṩÓмÛÖµµÄѭ֤ҽѧ֤¾Ý£¬£¬ £¬´Ó¶ø¸üºÃµØ¸ÄÉÆ»¼ÕßµÄÔ¤ºó¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://jnccn.org/view/journals/jnccn/aop/article-10.6004-jnccn.2021.7101/article-10.6004-jnccn.2021.7101.xml

¡¾ÍøÕ¾µØÍ¼¡¿